NeuroScientific Biopharmaceuticals (ASX:NSB) has reported encouraging results from two early studies of its StemSmart mesenchymal stromal cell (MSC) therapy in renal transplantation, reinforcing its potential to improve outcomes for patients facing the risks of graft rejection and transplant-related complications. …
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 Australian Biotech
Latest Video
New Stories
-
Cartherics secures Chinese patent to boost immune cell function in solid tumours
August 27, 2025 - - Australian Biotech -
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 - - Australian Biotech -
Starpharma advances dendrimer platform with clinical, commercial, and strategic progress
August 27, 2025 - - Australian Biotech -
Biome achieves breakthrough year with first profit and rapid global expansion
August 27, 2025 - - Australian Biotech -
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 - - Australian Biotech -
Sigma Healthcare delivers strong first-year results after Chemist Warehouse merger
August 27, 2025 - - Latest News -
Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push
August 27, 2025 - - Latest News